⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IFRX News
InflaRx N.V. Common Stock
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
globenewswire.com
IFRX
Organic & Natural Health to Address Policy, Integrity and Innovation at 2026 Industry Conference
globenewswire.com
IFRX
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
globenewswire.com
IFRX
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
globenewswire.com
IFRX
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
globenewswire.com
IFRX